Edgar Filing: CAVANAGH RICHARD - Form 4

CAVANAC Form 4 October 19,	H RICHARD										
FORM	14 UNITED	STATES		RITIES A			NGE	COMMISSION		PPROVA 3235-	-0287
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box if no longer STATEMENT OF CHANGES IN BENEFICIAL OW SECURITIES Filed pursuant to Section 16(a) of the Securities Exchang Section 17(a) of the Public Utility Holding Company Act of 194					nge Act of 1934, of 1935 or Sectio	Estimated burden hou response	Estimated average burden hours per response				
(Print or Type	Responses)										
	Address of Reporting GH RICHARD (First) (Person <u>*</u> Middle)	Symbol BLACI ALLOO [PSY] 3. Date of	er Name an KROCK (CATION of Earliest T	CREDI' INCON	Γ 1E TRU		5. Relationship of Issuer (Che X_ Director Officer (giv below)	ck all applicabl		
55 EAST 5	2ND STREET		(Month/Day/Year) 10/15/2010			· · · · · ,					
(Street) NEW YORK, NY 10055			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State)	(Zip)	Tab	le I - Non-J	Derivativ	e Securi	ties A	cquired, Disposed o	of. or Beneficia	llv Owne	d
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemo Execution any (Month/Da	ed Date, if	3. Transactic Code (Instr. 8)	4. Secur onAcquire Dispose (Instr. 3	ities d (A) or d of (D) , 4 and 5 (A) or)	5. Amount of Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature Indirect	e of al iip
Reminder: Re	port on a separate line	e for each cl	ass of sect	Code V urities bene	ficially o Pers infor requ	wned dire cons wh rmation lired to lays a c	o res cont respo	or indirectly. pond to the colle ained in this form ond unless the for atly valid OMB co	are not m	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities

Edgar Filing: CAVANAGH RICHARD - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed o (D) (Instr. 3, 4, and 5)	(Month/Day f	/Year)	(Instr. 3 and	4)
				Code V	(A) (D) Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Rights (1)	<u>(2)</u>	10/15/2010		А	114.07	(3)	(3)	Common Stock	114.07

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
CAVANAGH RICHARD 55 EAST 52ND STREET NEW YORK, NY 10055	Х					
Cianoturoo						

Signatures

/s/ Janey Ahn as Attorney-in-Fact	10/19/2010
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Performance Rights were accrued under the BlackRock Deferred Compensation Plan.
- (2) One Performance Right is convertible into the cash value of one share of BlackRock Credit Allocation Income Trust II, Inc.
- (3) The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. tyle="vertical-align: top; width: 34%; border-left: 0.5pt solid #000000; border-right: 0.5pt solid #000000; border-bottom: 2px solid #000000">

Volume(s) £0.00 49,152 d) Aggregated information n/a (single transaction) Aggregated volume Price

e) Date of the transaction 2018-04-26 f) Place of the transaction n/a

f)

1.	Details of PDMR/person closely associa	ated with ther	n ('PCA')		
a)	Name	Mr Roger C	onnor		
b)	Desition/status	President, Global			
	Position/status	Manufacturing & Supply			
c)	Initial notification/	Initial Notif	ication		
0)	amendment	Initial Notification			
2.	Details of the issuer, emission allowance	e market part	icipant, auction		
۷.	platform, auctioneer or auction monitor				
a)	Name	GlaxoSmith	Kline plc		
b)	LEI	5493000HZ	TVUYLO1D793		
	Details of the transaction(s): section to b	be repeated for	or (i) each type of		
3.	instrument; (ii) each type of transaction;	; (iii) each da	te; and (iv) each		
	place where transaction(s) has been con-	ducted			
		Ordinary sh	ares of 25 pence		
		each ('Ordinary Shares')			
a)	Description of the financial instrument				
		ISIN: GB0009252882			
			49,152 Ordinary		
b)	Nature of the transaction	Shares to spouse for nil			
		consideration.			
c	Price(s) and volume(s)	Price(s)	Volume(s)		
0)	Thee(s) and volume(s)	£0.00	49,152		
d)	Aggregated information	n/a (single t	ransaction)		
u)	Aggregated volume Price				
e)	Date of the transaction	2018-04-27			
	Dlags of the transportion				

Place of the transaction

	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Mrs Denise Connor		
		PCA of Mr Roger Connor		
b)	Position/status	(President, Global		
		Manufacturing & Supply)		
2	Initial notification/	Initial Natification		
c)	amendment	Initial Notification		
\mathbf{r}	Details of the issuer, emission allowance market participant, auction			
۷.	platform, auctioneer or auction monitor			
a)	Name	GlaxoSmithKline plc		
b)	LEI	5493000HZTVUYLO1D793		
	Details of the transaction(s): section to be repeated for (i) each type of			
3.	instrument; (ii) each type of transaction; (iii) each date; and (iv) each			
3.				

n/a

place where transaction(s) has been conducted

Explanation of Responses:

Edgar Filing: CAVANAGH RICHARD - Form 4

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

b) Nature of the transaction	Receipt of 49,152 Ordinary Shares from spouse for nil consideration.
c) Price(s) and volume(s)	Price(s) Volume(s) £0.00 49,152
d) Aggregated information Aggregated volume Price	n/a (single transaction)
e) Date of the transaction	2018-04-27
f) Place of the transaction	n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: April 27, 2018

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc